Routine next generation sequencing of lymphoid malignancies: clinical utility and challenges from a 3-Year practical experience

2020 ◽  
Vol 61 (11) ◽  
pp. 2568-2583 ◽  
Author(s):  
Vincent Pillonel ◽  
Darius Juskevicius ◽  
Michel Bihl ◽  
Frank Stenner ◽  
Jörg P. Halter ◽  
...  
Keyword(s):  
Next Generation Sequencing ◽  
Clinical Utility ◽  
Practical Experience ◽  
Next Generation ◽  
Lymphoid Malignancies ◽  
Generation Sequencing

scholarly journals The clinical utility of next-generation sequencing for identifying chromosome disease syndromes in human embryos

2015 ◽  
Vol 31 (1) ◽  
pp. 62-70 ◽  
Author(s):  
Junmei Fan ◽  
Li Wang ◽  
Hui Wang ◽  
Minyue Ma ◽  
Shufang Wang ◽  
...  
Keyword(s):  
Next Generation Sequencing ◽  
Clinical Utility ◽  
Human Embryos ◽  
Next Generation ◽  
Generation Sequencing

scholarly journals Next-Generation Sequencing Reveals Potentially Actionable Alterations in the Majority of Patients With Lymphoid Malignancies

2017 ◽  
pp. 1-13 ◽  
Author(s):  
Aaron M. Goodman ◽  
Michael Choi ◽  
Matthew Wieduwilt ◽  
Carolyn Mulroney ◽  
Caitlin Costello ◽  
...  
Keyword(s):  
Next Generation Sequencing ◽  
Median Number ◽  
Targeted Drugs ◽  
Next Generation ◽  
Lymphoid Malignancies ◽  
Tumor Mutational Burden ◽  
Approved Drugs ◽  
Next Generation Sequencing Ngs ◽  
Fda Approved Drugs ◽  
Generation Sequencing

Purpose Next-generation sequencing (NGS) identifies potentially targetable alterations by US Food and Drug Administration (FDA)–approved drugs and/or by available experimental agents that may not have otherwise been contemplated. Many targeted drugs have been developed for diverse solid cancers; a smaller number of genomically targeted drugs have been approved for lymphoid malignancies. Materials and Methods We analyzed NGS results from 60 patients with various lymphoid malignancies and found 224 alterations (median per patient, three alterations). Results Forty-nine patients (82%) had potentially actionable alterations with the use of FDA-approved drugs and/or experimental therapies; only 11 patients (18%) had no theoretically actionable alterations. Only three patients (5%) had an alteration for which an approved drug in the disease is available (on label); 45 patients (75%) had an alteration for which an approved drug is available for another disease (off label). The median number of alterations per patient potentially actionable by an FDA-approved drug was one. Of note, 19 (32%) of 60 patients had intermediate to high tumor mutational burden, which may predict response to certain immunotherapy agents. Conclusion NGS identifies alterations that may be pharmacologically tractable in most patients with lymphoid malignancies, albeit with drugs that have usually been developed in the context of solid tumors. These observations merit expanded exploration in the clinical trials setting.

Clinical utility of profiling somatic alterations in Indian cancer patients using a multi-gene next generation sequencing (NGS) test.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. e22127-e22127
Author(s):  
Urvashi Bahadur ◽  
Aarthi Ravichandran ◽  
Shataparna Banerjee ◽  
Shreya Paliwal ◽  
Roopa Rayanur Sripathi ◽  
...  
Keyword(s):  
Next Generation Sequencing ◽  
Cancer Patients ◽  
Clinical Utility ◽  
Next Generation ◽  
Somatic Alterations ◽  
Next Generation Sequencing Ngs ◽  
Generation Sequencing

Clinical utility of reflex testing using focused next generation sequencing for management of patients with advanced lung adenocarcinoma.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. e24199-e24199
Author(s):  
Navid Sadri ◽  
Tyler E Miller ◽  
Michael Yang ◽  
Afshin Dowlati ◽  
Judah D. Friedman ◽  
...  
Keyword(s):  
Next Generation Sequencing ◽  
Lung Adenocarcinoma ◽  
Clinical Utility ◽  
Next Generation ◽  
Reflex Testing ◽  
Generation Sequencing

scholarly journals The Clinical Utility of Next Generation Sequencing Results in a Community-Based Hereditary Cancer Risk Program

2016 ◽  
Vol 26 (1) ◽  
pp. 105-112 ◽  
Author(s):  
A. E. Bunnell ◽  
C. A. Garby ◽  
E. J. Pearson ◽  
S. A. Walker ◽  
L. E. Panos ◽  
...  
Keyword(s):  
Next Generation Sequencing ◽  
Cancer Risk ◽  
Hereditary Cancer ◽  
Clinical Utility ◽  
Next Generation ◽  
Community Based ◽  
Generation Sequencing

scholarly journals Clinical utility of next-generation sequencing in the diagnosis of hereditary haemolytic anaemias

2016 ◽  
Vol 174 (5) ◽  
pp. 806-814 ◽  
Author(s):  
Archana M. Agarwal ◽  
Roberto H. Nussenzveig ◽  
Noel S. Reading ◽  
Jay L. Patel ◽  
Nikhil Sangle ◽  
...  
Keyword(s):  
Next Generation Sequencing ◽  
Clinical Utility ◽  
Next Generation ◽  
Generation Sequencing
Sign in / Sign up

Export Citation Format

Share Document